Literature DB >> 1676282

HIV prevalence, immunosuppression, and drug resistance in patients with tuberculosis in an area endemic for AIDS.

R W Shafer1, K D Chirgwin, A E Glatt, M A Dahdouh, S H Landesman, B Suster.   

Abstract

From October 1987 to June 1988, we attempted to determine the prevalence of HIV infection among patients hospitalized with tuberculosis and the extent of immunosuppression among those tuberculosis patients infected with HIV. Of 178 consecutive patients, 18-65 years of age, who were hospitalized with newly diagnosed, previously untreated tuberculosis, 46% (82 out of 178) had clinical or serological evidence of HIV infection, 30% (54 out of 178) were HIV-seronegative, and 24% (42 out of 178) could not be assessed for the presence of HIV infection. Among the HIV-seropositive patients without an AIDS-defining diagnosis by non-tuberculous criteria, the median CD4 lymphocyte (CD4) count was 133 x 10(6) cells/l (range: 11-677 x 10(6]; among the HIV-seronegative patients, the median CD4 count was 613 x 10(6) cells/l (range: 238-1614 x 10(6); P less than 0.001). Among the HIV-seropositive patients, those with disseminated tuberculosis (median CD4 = 79 x 10(6) cells/l) and those with pulmonary tuberculosis who had radiographic evidence of mediastinal or hilar adenopathy (median CD4 = 45 x 10(6) cells/l) had the most severe CD4 depletion, whereas those with localized extrapulmonary tuberculosis (median CD4 = 242 x 10(6) cells/l) and those with pulmonary tuberculosis without adenopathy (median CD4 = 299 x 10(6) cells/l) were less severely immunosuppressed. Of the 178 patients, 6% (11 out of 178) were infected with strains of Mycobacterium tuberculosis resistant to both isoniazid and rifampin.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1676282     DOI: 10.1097/00002030-199104000-00007

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  13 in total

Review 1.  Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.

Authors:  W J Burman; K Gallicano; C Peloquin
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  Drug resistant tuberculosis: problems on the horizon.

Authors:  L P Ormerod
Journal:  Thorax       Date:  1993-10       Impact factor: 9.139

3.  Pulmonary Tuberculosis in HIV Infection : The Relationship of the Radiographic Appearance to CD4 T-Lymphocytes Count.

Authors:  K E San; M Muhamad
Journal:  Malays J Med Sci       Date:  2001-01

4.  Adjuvant modulation of immune responses to tuberculosis subunit vaccines.

Authors:  E B Lindblad; M J Elhay; R Silva; R Appelberg; P Andersen
Journal:  Infect Immun       Date:  1997-02       Impact factor: 3.441

5.  Universal HIV screening at a major metropolitan TB clinic: HIV prevalence and high-risk behaviors among TB patients.

Authors:  S E Weis; B Foresman; P E Cook; K J Matty
Journal:  Am J Public Health       Date:  1999-01       Impact factor: 9.308

6.  Immunological responses of Gambians in relation to clinical stage of HIV-2 disease.

Authors:  H Whittle; A Egboga; J Todd; G Morgan; M Rolfe; S Sabally; A Wilkins; T Corrah
Journal:  Clin Exp Immunol       Date:  1993-07       Impact factor: 4.330

Review 7.  Tuberculosis and HIV disease: two decades of a dual epidemic.

Authors:  Muktar H Aliyu; Hamisu M Salihu
Journal:  Wien Klin Wochenschr       Date:  2003-10-31       Impact factor: 1.704

Review 8.  Pediatric HIV infection: an imaging update.

Authors:  J O Haller; H L Cohen
Journal:  Pediatr Radiol       Date:  1994

Review 9.  Human immunodeficiency virus infection and tuberculosis: an analysis and a course of action.

Authors:  A B Bryt; D E Rogers
Journal:  Bull N Y Acad Med       Date:  1994

10.  A bacteriological survey of tuberculosis due to the human tubercle bacillus (Mycobacterium tuberculosis) in south-east England: 1984-91.

Authors:  M D Yates; J M Grange
Journal:  Epidemiol Infect       Date:  1993-06       Impact factor: 2.451

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.